821TiP GREAT: A multicentric cohort of advanced ovarian cancer (AOC) treated in real life with prospective collection of clinical data, tumor sample, and biomarkers (tBRCA, HRD) including genomic putative theranostic markers: A GINECO study

Abstract

In AOC, tumor genomic analyses such as testing for tumor BRCA mutation (tBRCAm) and homologous recombination repair deficiency (HRD) have become essential to select patients (pts) who will derive the greatest benefit from maintenance PARP inhibitor treatment, particularly in first-line. However, a better understanding of specific genomic alterations beyond BRCA and their impact on disease progression is of a critical importance for the next generation drug development and patient outcome improvement.